Cardiff Oncology Inc (CRDF)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $65.95M
Last updated: Nov 17, 2026 at 4:39 PM ET
Cardiff Oncology Inc (CRDF) Statistics
Cardiff Oncology (CRDF) has a market cap of $65.95M and an enterprise value of $53.89M. It kept -6735.24% of revenue as net income over the last 12 months. Its share count is up 13.90% from a year earlier.
Total Valuation
Enterprise value is 18.29% below the market cap, as cash exceeds debt.
| Market Cap | $65.95M |
|---|---|
| Enterprise Value | $53.89M |
| Latest price (Nov 17, 2026) | $0.85 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 115.3x and 2.3x. Its year-end P/S ranged from 11.8x to 866.8x from 2016 to 2025.
| P/S Ratio | 115.3x |
|---|---|
| Forward P/S | 180.9x |
| P/B Ratio | 2.3x |
Price Statistics
The stock is down 60.26% over 52 weeks and trades 17.48% below its 50-day average.
| Beta (1Y) | 1.64 |
|---|---|
| 52-Week Change | -60.26% |
| 1-Month Change | -4.44% |
| 3-Month Change | -5.74% |
| 6-Month Change | -51.91% |
| 5-Year Change | -84.84% |
| 10-Year Change | -99.64% |
| Total Return (1Y) | -60.26% |
| Total Return (3Y CAGR) | -10.98% |
| Total Return (5Y CAGR) | -32.89% |
| Max Drawdown (1Y) | -77.38% |
| Max Drawdown (3Y) | -87.71% |
| Sharpe Ratio (1Y) | -0.93 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $1.03 |
| 200-Day Average | $1.34 |
| 52-Week Range | $0.71 to $3.31 |
| RSI (14 Days) | 46.5 |
| Average Volume (20 Days) | 1.71M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.21x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.21x |
|---|---|
| Quick Ratio | 4.21x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -134.00% over the last 12 months, against a 5-year average of -54.35%.
| Return on Equity (ROE) | -134.00% |
|---|---|
| Return on Assets (ROA) | -103.39% |
| ROE (5Y Average) | -54.35% |
| ROA (5Y Average) | -44.77% |
| ROIC (5Y Average) | -85.21% |
| Asset Turnover | 0.01x |
| Receivables Turnover | 4.01x |
Scores
CRDF has an Altman Z-Score of -15.74, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -15.74 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $559.00K over the last 12 months is up 11.80% from the 12 months before.
| Revenue | $559.00K |
|---|---|
| Revenue Growth (YoY) | +11.80% |
| Gross Profit | $559.00K |
| Operating Income | -$39.51M |
| Pretax Income | -$37.65M |
| Net Income | -$37.65M |
| Reported EPS (TTM) | -$0.55 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.18% of the $36.41M in total assets.
| Cash and Equivalents | $12.06M |
|---|---|
| Total Debt | $0 |
| Net Cash | $12.06M |
| Net Cash Per Share | $0.16 |
| Working Capital | $26.71M |
| Shareholder Equity | $28.10M |
| Book Value Per Share | $0.37 |
| Total Assets | $36.41M |
| Total Liabilities | $8.32M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $48.00K of capital spending, operating cash flow left -$39.94M of free cash flow.
| Operating Cash Flow | -$39.89M |
|---|---|
| Capital Expenditures | $48.00K |
| Free Cash Flow | -$39.94M |
| FCF Per Share | -$0.51 |
| Depreciation and Amortization | $1.14M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -7068.16%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -7068.16% |
| Pretax Margin | -6735.24% |
| Net Margin | -6735.24% |
| FCF Margin | -7145.26% |
Growth
Revenue grew 15.39% a year over 3 years.
| Revenue Growth (3Y CAGR) | +15.39% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.13% |
| Book Value Per Share Growth (2Y CAGR) | -34.04% |
| Tangible Book Per Share Growth (2Y CAGR) | -34.04% |
Dividends and Yields
CRDF does not pay a dividend. Its free cash flow yield is -61.95%.
| FCF Yield | -61.95% |
|---|---|
| Buyback Yield | 1.25% |
| Shareholder Yield | 1.25% |
Stock Splits
The last split was a 1-for-6 reverse split on Feb 20, 2019.
| Last Split Date | Feb 20, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 5 similar companies, CRDF has the highest P/S.
P/S RatioPeer median 12.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -21.38%
| P/S Ratio | 115.3x vs 12.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.80% vs -21.38% median |
Analyst Forecast
Consensus estimates put revenue growth at -19.42% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -19.42% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CRDF
What is CRDF's market cap?
Cardiff Oncology has a market cap of $65.95M. Its enterprise value, which adds debt and subtracts cash, is $53.89M.
How many shares of CRDF are outstanding?
Cardiff Oncology has 76.18M shares outstanding. The count is up 13.90% from a year earlier.
Does CRDF pay a dividend?
No. Cardiff Oncology does not pay a dividend.
How much debt does CRDF have?
Cardiff Oncology has $0 of total debt and $12.06M of cash and equivalents, a net cash position of $12.06M.
CRDF pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors